Raptor Announces Clinical Results With RP103 in Huntington’s Disease Phase 2/3 Trial

[GlobeNewswire] – 18 Month Clinical Results Showed Significantly Slower Progression of Total Motor Score in RP103 Treated Patients Without Tetrabenazine more

View todays social media effects on RPTP

View the latest stocks trending across Twitter. Click to view dashboard

See who Raptor is hiring next, click here to view